{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:13:28Z","timestamp":1773393208420,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12264-021-00749-x","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T13:02:40Z","timestamp":1627390960000},"page":"1735-1744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hot Topics in Recent Parkinson\u2019s Disease Research: Where We are and Where We Should Go"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-9136","authenticated-orcid":false,"given":"Song","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-6373","authenticated-orcid":false,"given":"Tianbai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7459-2705","authenticated-orcid":false,"given":"Weidong","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","volume":"66","author":"JM Miyasaki","year":"2006","unstructured":"Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66: 996\u20131002.","journal-title":"Neurology"},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM. Epidemiology of Parkinson\u2019s disease. Lancet Neurol 2006, 5: 525\u2013535.","journal-title":"Lancet Neurol"},{"key":"749_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: a review. JAMA 2020, 323: 548\u2013560.","journal-title":"JAMA"},{"key":"749_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.chest.2020.09.099","volume":"159","author":"AC Lajoie","year":"2021","unstructured":"Lajoie AC, Lafontaine AL, Kaminska M. The spectrum of sleep disorders in parkinson disease: a review. Chest 2021, 159: 818\u2013827.","journal-title":"Chest"},{"key":"749_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","volume":"15","author":"A Elkouzi","year":"2019","unstructured":"Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease\u2014repurposed drugs and new approaches. Nat Rev Neurol 2019, 15: 204\u2013223.","journal-title":"Nat Rev Neurol"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/mds.27705","volume":"34","author":"A Latorre","year":"2019","unstructured":"Latorre A, Rocchi L, Berardelli A, Bhatia KP, Rothwell JC. The use of transcranial magnetic stimulation as a treatment for movement disorders: a critical review. Mov Disord 2019, 34: 769\u2013782.","journal-title":"Mov Disord"},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/mds.27736","volume":"34","author":"A Latorre","year":"2019","unstructured":"Latorre A, Rocchi L, Berardelli A, Bhatia KP, Rothwell JC. The interindividual variability of transcranial magnetic stimulation effects: implications for diagnostic use in movement disorders. Mov Disord 2019, 34: 936\u2013949.","journal-title":"Mov Disord"},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s13311-020-00940-4","volume":"17","author":"PC Buttery","year":"2020","unstructured":"Buttery PC, Barker RA. Gene and cell-based therapies for Parkinson\u2019s disease: where are we? Neurotherapeutics 2020, 17: 1539\u20131562.","journal-title":"Neurotherapeutics"},{"key":"749_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 2003, 24: 197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 2004, 318: 121\u2013134.","journal-title":"Cell Tissue Res"},{"key":"749_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nrneurol.2010.145","volume":"6","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 2010, 6: 702\u2013706.","journal-title":"Nat Rev Neurol"},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338: 949\u2013953.","journal-title":"Science"},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson E, Horv\u00e1th-Puh\u00f3 E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, et al. Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann Neurol 2015, 78: 522\u2013529.","journal-title":"Ann Neurol"},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 2019, 103: 627-641.e7.","journal-title":"Neuron"},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"D James Surmeier","year":"2017","unstructured":"James Surmeier D, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017, 18: 101\u2013113.","journal-title":"Nat Rev Neurosci"},{"key":"749_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","volume":"571","author":"D Matheoud","year":"2019","unstructured":"Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, et al. Intestinal infection triggers Parkinson\u2019s disease-like symptoms in Pink1\u2212\/\u2212 mice. Nature 2019, 571: 565\u2013569.","journal-title":"Nature"},{"key":"749_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease. Nat Commun 2019, 10: 310.","journal-title":"Nat Commun"},{"key":"749_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbi.2018.02.016","volume":"70","author":"YW Qian","year":"2018","unstructured":"Qian YW, Yang XD, Xu SQ, Wu CY, Song YY, Qin N, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson\u2019s disease. Brain Behav Immun 2018, 70: 194\u2013202.","journal-title":"Brain Behav Immun"},{"key":"749_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/mds.27105","volume":"33","author":"A Heintz-Buschart","year":"2018","unstructured":"Heintz-Buschart A, Pandey U, Wicke T, Sixel-D\u00f6ring F, Janzen A, Sittig-Wiegand E, et al. The nasal and gut microbiome in Parkinson\u2019s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord 2018, 33: 88\u201398.","journal-title":"Mov Disord"},{"key":"749_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","volume":"70","author":"MF Sun","year":"2018","unstructured":"Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: Gut microbiota, glial reaction and TLR4\/TNF-\u03b1 signaling pathway. Brain Behav Immun 2018, 70: 48\u201360.","journal-title":"Brain Behav Immun"},{"key":"749_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter I, Dubinsky M, Bressman S, Park A, Lu CY, Chen NJ, et al. Anti-tumor necrosis factor therapy and incidence of parkinson disease among patients with inflammatory bowel disease. JAMA Neurol 2018, 75: 939\u2013946.","journal-title":"JAMA Neurol"},{"key":"749_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-017-1777-8","volume":"135","author":"A Lionnet","year":"2018","unstructured":"Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, et al. Does Parkinson\u2019s disease start in the gut? Acta Neuropathol 2018, 135: 1\u201312.","journal-title":"Acta Neuropathol"},{"key":"749_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1073858418783959","volume":"25","author":"MK Jha","year":"2019","unstructured":"Jha MK, Jo M, Kim JH, Suk K. Microglia-astrocyte crosstalk: an intimate molecular conversation. Neuroscientist 2019, 25: 227\u2013240.","journal-title":"Neuroscientist"},{"key":"749_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017, 541: 481\u2013487.","journal-title":"Nature"},{"key":"749_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med 2018, 24: 931\u2013938.","journal-title":"Nat Med"},{"key":"749_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nri.2017.125","volume":"18","author":"Q Li","year":"2018","unstructured":"Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol 2018, 18: 225\u2013242.","journal-title":"Nat Rev Immunol"},{"key":"749_CR27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.4397","volume":"23","author":"MW Salter","year":"2017","unstructured":"Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med 2017, 23: 1018\u20131027.","journal-title":"Nat Med"},{"key":"749_CR28","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1093\/brain\/awaa269","volume":"143","author":"J Galiano-Landeira","year":"2020","unstructured":"Galiano-Landeira J, Torra A, Vila M, Bov\u00e9 J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain 2020, 143: 3717\u20133733.","journal-title":"Brain"},{"key":"749_CR29","doi-asserted-by":"crossref","unstructured":"Lee SYH, Yates NJ, Tye SJ. Inflammatory mechanisms in Parkinson's disease: from pathogenesis to targeted therapies. Neuroscientist 2021: 107385842199226.","DOI":"10.1177\/1073858421992265"},{"key":"749_CR30","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1038\/s41467-019-11928-w","volume":"10","author":"P Krashia","year":"2019","unstructured":"Krashia P, Cordella A, Nobili A, La Barbera L, Federici M, Leuti A, et al. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson\u2019s disease. Nat Commun 2019, 10: 3945.","journal-title":"Nat Commun"},{"key":"749_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/med.21714","volume":"41","author":"C Bento-Pereira","year":"2021","unstructured":"Bento-Pereira C, Dinkova-Kostova AT. Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson\u2019s disease. Med Res Rev 2021, 41: 785\u2013802.","journal-title":"Med Res Rev"},{"key":"749_CR32","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41418-020-00688-6","volume":"28","author":"MD Demmings","year":"2021","unstructured":"Demmings MD, Tennyson EC, Petroff GN, Tarnowski-Garner HE, Cregan SP. Activating transcription factor-4 promotes neuronal death induced by Parkinson\u2019s disease neurotoxins and \u03b1-synuclein aggregates. Cell Death Differ 2021, 28: 1627\u20131643.","journal-title":"Cell Death Differ"},{"key":"749_CR33","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/glia.23826","volume":"68","author":"J Dong","year":"2020","unstructured":"Dong J, Liu X, Wang Y, Cai H, Le W. Nurr1Cd11bcre conditional knockout mice display inflammatory injury to nigrostriatal dopaminergic neurons. Glia 2020, 68: 2057\u20132069.","journal-title":"Glia"},{"key":"749_CR34","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1093\/brain\/awaa283","volume":"143","author":"Y Shen","year":"2020","unstructured":"Shen Y, Yu WB, Shen B, Dong H, Zhao J, Tang YL, et al. Propagated \u03b1-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice. Brain 2020, 143: 3374\u20133392.","journal-title":"Brain"},{"key":"749_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mds.28318","volume":"36","author":"K Mufti","year":"2021","unstructured":"Mufti K, Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, et al. Comprehensive analysis of familial Parkinsonism genes in rapid-eye-movement sleep behavior disorder. Mov Disord 2021, 36: 235\u2013240.","journal-title":"Mov Disord"},{"key":"749_CR36","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mds.28412","volume":"36","author":"M Elfil","year":"2021","unstructured":"Elfil M, Bahbah EI, Attia MM, Eldokmak M, Koo BB. Impact of obstructive sleep apnea on cognitive and motor functions in Parkinson\u2019s disease. Mov Disord 2021, 36: 570\u2013580.","journal-title":"Mov Disord"},{"key":"749_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol 2020, 19: 170\u2013178.","journal-title":"Lancet Neurol"},{"key":"749_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","volume":"42","author":"H Deng","year":"2018","unstructured":"Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev 2018, 42: 72\u201385.","journal-title":"Ageing Res Rev"},{"key":"749_CR39","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","volume":"77","author":"JN Foo","year":"2020","unstructured":"Foo JN, Chew EGY, Chung SJ, Peng R, Blauwendraat C, Nalls MA, et al. Identification of risk loci for parkinson disease in asians and comparison of risk between asians and Europeans: A genome-wide association study. JAMA Neurol 2020, 77: 746\u2013754.","journal-title":"JAMA Neurol"},{"key":"749_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mds.28342","volume":"36","author":"MMX Tan","year":"2021","unstructured":"Tan MMX, Lawton MA, Jabbari E, Reynolds RH, Iwaki H, Blauwendraat C, et al. Genome-wide association studies of cognitive and motor progression in Parkinson\u2019s disease. Mov Disord 2021, 36: 424\u2013433.","journal-title":"Mov Disord"},{"key":"749_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41586-021-03185-z","volume":"591","author":"J Wie","year":"2021","unstructured":"Wie J, Liu ZJ, Song HK, Tropea TF, Yang L, Wang HH, et al. A growth-factor-activated lysosomal K+ channel regulates Parkinson\u2019s pathology. Nature 2021, 591: 431\u2013437.","journal-title":"Nature"},{"key":"749_CR42","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mds.27659","volume":"34","author":"C Blauwendraat","year":"2019","unstructured":"Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstr\u00f8m L, et al. Parkinson\u2019s disease age at onset genome-wide association study: defining heritability, genetic loci, and \u03b1-synuclein mechanisms. Mov Disord 2019, 34: 866\u2013875.","journal-title":"Mov Disord"},{"key":"749_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019, 18: 1091\u20131102.","journal-title":"Lancet Neurol"},{"key":"749_CR44","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"B Kantor","year":"2018","unstructured":"Kantor B, Tagliafierro L, Gu J, Zamora ME, Ilich E, Grenier C, et al. Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD. Mol Ther 2018, 26: 2638\u20132649.","journal-title":"Mol Ther"},{"key":"749_CR45","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/hmg\/ddr210","volume":"20","author":"E Mi\u00f1ones-Moyano","year":"2011","unstructured":"Mi\u00f1ones-Moyano E, Porta S, Escaram\u00eds G, Rabionet R, Iraola S, Kagerbauer B, et al. MicroRNA profiling of Parkinson\u2019s disease brains identifies early downregulation of miR-34b\/c which modulate mitochondrial function. Hum Mol Genet 2011, 20: 3067\u20133078.","journal-title":"Hum Mol Genet"},{"key":"749_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13024-016-0121-4","volume":"11","author":"J Kim","year":"2016","unstructured":"Kim J, Fiesel FC, Belmonte KC, Hudec R, Wang WX, Kim C, et al. miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1). Mol Neurodegener 2016, 11: 55.","journal-title":"Mol Neurodegener"},{"key":"749_CR47","doi-asserted-by":"publisher","first-page":"105197","DOI":"10.1016\/j.phrs.2020.105197","volume":"160","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhao Y, Li Z, Zhu M, Wang Z, Li Y, et al. miR-103a-3p regulates mitophagy in Parkinson\u2019s disease through Parkin\/Ambra1 signaling. Pharmacol Res 2020, 160: 105197.","journal-title":"Pharmacol Res"},{"key":"749_CR48","doi-asserted-by":"publisher","first-page":"e13140","DOI":"10.1111\/acel.13140","volume":"19","author":"K Goljanek-Whysall","year":"2020","unstructured":"Goljanek-Whysall K, Soriano-Arroquia A, McCormick R, Chinda C, McDonagh B. miR-181a regulates p62\/SQSTM1, parkin, and protein DJ-1 promoting mitochondrial dynamics in skeletal muscle aging. Aging Cell 2020, 19: e13140.","journal-title":"Aging Cell"},{"key":"749_CR49","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"SP Sardi","year":"2018","unstructured":"Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic. Mov Disord 2018, 33: 684\u2013696.","journal-title":"Mov Disord"},{"key":"749_CR50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","volume":"92","author":"AJ Espay","year":"2019","unstructured":"Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 2019, 92: 329\u2013337.","journal-title":"Neurology"},{"key":"749_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.expneurol.2010.06.017","volume":"225","author":"J Wills","year":"2010","unstructured":"Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia. Exp Neurol 2010, 225: 210\u2013218.","journal-title":"Exp Neurol"},{"key":"749_CR52","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.26562","volume":"31","author":"T Moors","year":"2016","unstructured":"Moors T, Paciotti S, Chiasserini D, Calabresi P, Parnetti L, Beccari T, et al. Lysosomal dysfunction and \u03b1-synuclein aggregation in Parkinson\u2019s disease: diagnostic links. Mov Disord 2016, 31: 791\u2013801.","journal-title":"Mov Disord"},{"key":"749_CR53","doi-asserted-by":"publisher","first-page":"E2634","DOI":"10.1073\/pnas.1713849115","volume":"115","author":"D Grassi","year":"2018","unstructured":"Grassi D, Howard S, Zhou M, Diaz-Perez N, Urban NT, Guerrero-Given D, et al. Identification of a highly neurotoxic \u03b1-synuclein species inducing mitochondrial damage and mitophagy in Parkinson\u2019s disease. PNAS 2018, 115: E2634\u2013E2643.","journal-title":"PNAS"},{"key":"749_CR54","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/hmg\/ddz080","volume":"28","author":"W Yi","year":"2019","unstructured":"Yi W, MacDougall EJ, Tang MY, Krahn AI, Gan-Or Z, Trempe JF, et al. The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson\u2019s disease. Hum Mol Genet 2019, 28: 2811\u20132825.","journal-title":"Hum Mol Genet"},{"key":"749_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease. Cell 2017, 171: 273\u2013285.","journal-title":"Cell"},{"key":"749_CR56","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012, 149: 1060\u20131072.","journal-title":"Cell"},{"key":"749_CR57","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.pneurobio.2020.101890","volume":"196","author":"L Mahoney-S\u00e1nchez","year":"2021","unstructured":"Mahoney-S\u00e1nchez L, Bouchaoui H, Ayton S, Devos D, Duce JA, Devedjian JC. Ferroptosis and its potential role in the physiopathology of Parkinson\u2019s Disease. Prog Neurobiol 2021, 196: 101890.","journal-title":"Prog Neurobiol"},{"key":"749_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.freeradbiomed.2018.09.033","volume":"133","author":"S Masaldan","year":"2019","unstructured":"Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C. Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med 2019, 133: 221\u2013233.","journal-title":"Free Radic Biol Med"},{"key":"749_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000511207","volume":"20","author":"M Zhang","year":"2020","unstructured":"Zhang M, He Q, Chen G, Li PA. Suppression of NLRP3 inflammasome, pyroptosis, and cell death by NIM811 in rotenone-exposed cells as an in vitro model of Parkinson\u2019s disease. Neurodegener Dis 2020, 20: 73\u201383.","journal-title":"Neurodegener Dis"},{"key":"749_CR60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12264-017-0184-4","volume":"33","author":"S Li","year":"2017","unstructured":"Li S, Le W. Biomarker discovery in Parkinson\u2019s disease: present challenges and future opportunities. Neurosci Bull 2017, 33: 481\u2013482.","journal-title":"Neurosci Bull"},{"key":"749_CR61","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12264-019-00433-1","volume":"36","author":"T Li","year":"2020","unstructured":"Li T, Le W. Biomarkers for Parkinson\u2019s disease: how good are they? Neurosci Bull 2020, 36: 183\u2013194.","journal-title":"Neurosci Bull"},{"key":"749_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C, et al. Development of a biochemical diagnosis of parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 2017, 74: 163\u2013172.","journal-title":"JAMA Neurol"},{"key":"749_CR63","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 2019, 18: 573\u2013586.","journal-title":"Lancet Neurol"},{"key":"749_CR64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-018-0304-2","volume":"14","author":"Y Shao","year":"2019","unstructured":"Shao Y, Le W. Recent advances and perspectives of metabolomics-based investigations in Parkinson\u2019s disease. Mol Neurodegener 2019, 14: 3.","journal-title":"Mol Neurodegener"},{"key":"749_CR65","doi-asserted-by":"publisher","first-page":"10927","DOI":"10.1007\/s00521-018-3689-5","volume":"32","author":"SL Oh","year":"2020","unstructured":"Oh SL, Hagiwara Y, Raghavendra U, Yuvaraj R, Arunkumar N, Murugappan M, et al. A deep learning approach for Parkinson\u2019s disease diagnosis from EEG signals. Neural Comput Appl 2020, 32: 10927\u201310933.","journal-title":"Neural Comput Appl"},{"key":"749_CR66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao Y, Li T, Liu Z, Wang X, Xu X, Li S, et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol Neurodegener 2021, 16: 4.","journal-title":"Mol Neurodegener"},{"key":"749_CR67","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang AE, Espay AJ. Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord 2018, 33: 660\u2013677.","journal-title":"Mov Disord"},{"key":"749_CR68","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/acs.chemrev.8b00138","volume":"119","author":"MG Savelieff","year":"2019","unstructured":"Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis in the last decade. Chem Rev 2019, 119: 1221\u20131322.","journal-title":"Chem Rev"},{"key":"749_CR69","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/cns.12536","volume":"22","author":"J Dong","year":"2016","unstructured":"Dong J, Li S, Mo JL, Cai HB, Le WD. Nurr1-based therapies for Parkinson\u2019s disease. CNS Neurosci Ther 2016, 22: 351\u2013359.","journal-title":"CNS Neurosci Ther"},{"key":"749_CR70","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1007\/s12035-019-1487-4","volume":"56","author":"M Jakaria","year":"2019","unstructured":"Jakaria M, Haque ME, Cho DY, Azam S, Kim IS, Choi DK. Molecular insights into NR4A2(Nurr1): An emerging target for neuroprotective therapy against neuroinflammation and neuronal cell death. Mol Neurobiol 2019, 56: 5799\u20135814.","journal-title":"Mol Neurobiol"},{"key":"749_CR71","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41467-018-03733-8","volume":"9","author":"R Kojima","year":"2018","unstructured":"Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson\u2019s disease treatment. Nat Commun 2018, 9: 1305.","journal-title":"Nat Commun"},{"key":"749_CR72","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with parkinson disease: A randomized clinical trial. JAMA Neurol 2018, 75: 1206\u20131214.","journal-title":"JAMA Neurol"},{"key":"749_CR73","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41565-018-0179-y","volume":"13","author":"D Kim","year":"2018","unstructured":"Kim D, Yoo JM, Hwang H, Lee J, Lee SH, Yun SP, et al. Graphene quantum dots prevent \u03b1-synucleinopathy in Parkinson\u2019s disease. Nat Nanotechnol 2018, 13: 812\u2013818.","journal-title":"Nat Nanotechnol"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-021-00749-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12264-021-00749-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-021-00749-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T08:26:16Z","timestamp":1675585576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12264-021-00749-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s12264-021-00749-x","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}